



OPEN ACCESS

Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study

Rafel Ramos,¹⁻⁴ Marc Comas-Cufí,^{1,2} Ruth Martí-Lluch,¹⁻³ Elisabeth Balló,¹⁻⁴ Anna Ponjoan,¹⁻³ Lia Alves-Cabratosa,^{1,2} Jordi Blanch,^{1,2} Jaume Marrugat,^{5,6} Roberto Elosua,^{5,6} María Grau,^{5,6} Marc Elosua-Bayes,^{1,2} Luis García-Ortiz,⁷ Maria Garcia-Gil²⁻⁴

For numbered affiliations see end of article.

Correspondence to: R Ramos, Carrer Maluquer Salvador, 11. 17002 Girona, Spain rramos.girona.ics@gencat.cat (ORCID 0000-0001-7970-5537)

Additional material is published online only. To view please visit the journal online.

Cite this as: *BMJ* 2018;362:k3359 <http://dx.doi.org/10.1136/bmj.k3359>

Accepted: 17 July 2018

ABSTRACT OBJECTIVE

To assess whether statin treatment is associated with a reduction in atherosclerotic cardiovascular disease (CVD) and mortality in old and very old adults with and without diabetes.

DESIGN

Retrospective cohort study.

SETTING

Database of the Catalan primary care system (SIDIAP), Spain, 2006-15.

PARTICIPANTS

46 864 people aged 75 years or more without clinically recognised atherosclerotic CVD. Participants were stratified by presence of type 2 diabetes mellitus and as statin non-users or new users.

MAIN OUTCOME MEASURES

Incidences of atherosclerotic CVD and all cause mortality compared using Cox proportional hazards modelling, adjusted by the propensity score of statin treatment. The relation of age with the effect of statins was assessed using both a categorical approach, stratifying the analysis by old (75-84 years) and very old (≥ 85 years) age groups, and a continuous analysis, using an additive Cox proportional hazard model.

RESULTS

The cohort included 46 864 participants (mean age 77 years; 63% women; median follow-up 5.6 years). In participants without diabetes, the hazard ratios

for statin use in 75-84 year olds were 0.94 (95% confidence interval 0.86 to 1.04) for atherosclerotic CVD and 0.98 (0.91 to 1.05) for all cause mortality, and in those aged 85 and older were 0.93 (0.82 to 1.06) and 0.97 (0.90 to 1.05), respectively. In participants with diabetes, the hazard ratio of statin use in 75-84 year olds was 0.76 (0.65 to 0.89) for atherosclerotic CVD and 0.84 (0.75 to 0.94) for all cause mortality, and in those aged 85 and older were 0.82 (0.53 to 1.26) and 1.05 (0.86 to 1.28), respectively. Similarly, effect analysis of age in a continuous scale, using splines, corroborated the lack of beneficial statins effect for atherosclerotic CVD and all cause mortality in participants without diabetes older than 74 years. In participants with diabetes, statins showed a protective effect against atherosclerotic CVD and all cause mortality; this effect was substantially reduced beyond the age of 85 years and disappeared in nonagenarians.

CONCLUSIONS

In participants older than 74 years without type 2 diabetes, statin treatment was not associated with a reduction in atherosclerotic CVD or in all cause mortality, even when the incidence of atherosclerotic CVD was statistically significantly higher than the risk thresholds proposed for statin use. In the presence of diabetes, statin use was statistically significantly associated with reductions in the incidence of atherosclerotic CVD and in all cause mortality. This effect decreased after age 85 years and disappeared in nonagenarians.

Introduction

Cardiovascular disease (CVD) is the leading cause of death globally.¹ Older populations are especially vulnerable to CVD, with incidence and mortality rates almost three times higher in those older than 74 years than in younger people.² In addition, projections of population growth anticipate that people older than 74 years will represent more than 10% of the population in developed countries in 2050.³ Consequently, prevention of CVD in this population will be a major worldwide health policy challenge during the next decades.

Evidence from randomised clinical trials and meta-analysis supports statin treatment for the secondary prevention of CVD in those aged 75 years and older.⁴⁻⁷ Data from meta-analyses also support statins for the primary prevention of CVD in those aged 65 years or more.^{8,9} This evidence does not, however, include people older than 74 years, and especially those older

WHAT IS ALREADY KNOWN ON THIS TOPIC

The efficiency of statins in reducing any cardiovascular event and also cardiovascular mortality in secondary prevention in those aged 75 years or older is well established

Statin prescriptions to elderly patients have increased in recent decades

Evidence on the effects of statins in primary prevention in those older than 74 years and particularly in those aged 85 years or older is lacking

WHAT THIS STUDY ADDS

Statins were not associated with a reduction in atherosclerotic cardiovascular disease (CVD) or all cause mortality in primary prevention in people without diabetes older than 74 years independently of age subgroup

Statins were significantly related to a reduction in incidence of atherosclerotic CVD and in all cause mortality in people with type 2 diabetes mellitus; this effect was substantially reduced after the age of 85 and disappeared in nonagenarians

These results do not support the widespread use of statins in old and very old populations, but they do support treatment in those with diabetes who are younger than 85 years

than 84 years—an age group that is underrepresented in clinical trials and observational studies.¹⁰ People aged 85 years and older represent a rapidly increasing portion of the population worldwide and many experience disease and disability, with heavy costs in health and social care.¹¹ Recent reports from post hoc secondary analyses of data from the Lipid-Lowering Trial component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) showed no benefit of pravastatin in primary prevention in adults aged 75 years and older.¹²

This concern also applies to older patients with type 2 diabetes mellitus—a particularly high risk group in primary prevention of CVD. Those with longstanding diabetes have a risk of coronary heart disease similar to that of patients with a history of coronary heart disease.¹³ Still, the benefit of statins in primary prevention in older people with diabetes has not been sufficiently evaluated.¹⁴ Notwithstanding this uncertainty, the number of prescriptions for statins in those aged 75 years or older have increased in recent decades.^{15 16} Moreover, current recommendations of the most implemented guidelines on cardiovascular prevention classify almost all patients aged 75 years or older as eligible for statin treatment based on 10 year risk estimation, because CVD incidence (ie, risk) is highly dependent on age.¹⁷⁻²⁰

The older population might also be more susceptible to adverse effects and drug interactions owing to comorbidities and polypharmacy, although these aspects have been poorly studied.²¹ In this scenario, decisions on statin use in people older than 74 years are made individually and are not supported by high quality evidence; further research is needed.¹⁷ We assessed whether the use of statins was associated with a reduced incidence of atherosclerotic CVD and mortality in older people initially free of CVD, by type 2 diabetes and age.

Methods

We carried out a retrospective cohort study using data from the Spanish Information System for the Development of Research in Primary Care (SIDIAP). This is a clinical database of anonymised longitudinal patient records of more than six million people (80% of the Catalan population and 10% of the total population of Spain) registered in 274 primary care practices and with a total of 3414 general practitioners.²² A subset of records from general practitioners who surpass predefined data quality standards²³ constitutes the SIDIAP^Q, which provides research quality anonymised data on approximately two million patients, attended by 1365 general practitioners, yielding nearly 14 million person years of clinical data for 2005-15.

The information recorded includes demographic and lifestyle factors relevant to primary care settings (eg, body mass index, smoking status, alcohol use); clinical diagnoses, outcomes, and events (coded according to the international classification of diseases, 10th revision); referrals and hospital discharge information (international classification of diseases,

ninth revision); laboratory tests; and prescribed drugs that have been dispensed by community pharmacies. The high quality of SIDIAP^Q data has been previously validated and the database has been widely used to study the epidemiology of several health outcomes.²⁴⁻²⁶ Confidentiality in the SIDIAP^Q database is rigorously assured by a standardised system of codification that involves all possible identifier variables, which are not available to investigators.

Study population and criteria for inclusion and exclusion

All individuals registered on SIDIAP^Q aged 75 years or older with at least one visit recorded in the electronic medical records during the 1.5 years before the index date were eligible for inclusion. We excluded those with a history of CVD, defined as any of several conditions: symptomatic peripheral arterial disease, ischaemic and haemorrhagic stroke, heart failure, and coronary heart disease, including non-fatal angina, non-fatal myocardial infarction, or cardiac revascularisation. We also excluded participants taking drugs to treat cardiac diseases (Anatomical Therapeutic Chemical code C01), those with type 1 diabetes and a history of lipid lowering treatment (statins or others), and, to avoid frailty bias, people with cancer, dementia, or paralysis, and those receiving dialysis, living in residential care, or with an organ transplant.

Statin use

To prevent survivor bias and covariate measurement bias, we selected a “new users design” over “all statin users.”²⁷ We defined a new user as anyone who received statin treatment (simvastatin, pravastatin, lovastatin, fluvastatin, rosuvastatin, atorvastatin) for the first time ever, or who initiated statin treatment with no such pharmacy invoicing recorded during the previous 18 months. We included those with at least two invoices for statins during the enrolment period. In descriptive analysis, we stratified the exposure of patients to statins according to the cholesterol reduction capacity of these drugs: low ($\leq 30\%$), moderate (31-40%), high (41-50%), and very high ($>50\%$).²⁸

Study entry and follow-up

The study period started in July 2006, with enrolment to the end of December 2007 and follow-up to the end of December 2015. People who moved from the primary care practices that provide data to SIDIAP^Q, were accordingly transferred from SIDIAP^Q and thus considered to be lost to follow-up. For statin users, index date was the date of the first statin invoice; for non-users, we selected the index date at random according to the distribution of the index date for statin users.

Outcomes

We identified the onset of cardiovascular diseases during follow-up using relevant SIDIAP^Q codes in both primary care and hospital discharge records. Primary outcomes were total mortality and atherosclerotic CVD,

a composite of coronary heart disease (fatal and non-fatal angina, fatal and non-fatal myocardial infarction, or cardiac revascularisation), and stroke (fatal and non-fatal ischaemic stroke). We also considered coronary heart disease and ischaemic stroke separately, as secondary outcomes.

Adverse effects

Liver toxicity and myopathy were considered attributable to statins if they occurred within 12 months of treatment initiation. If the diagnosis of new onset type 2 diabetes, cancer, and haemorrhagic stroke occurred after one year we considered these more likely to be associated with long term use and thus attributable to statin use.²⁹

Baseline covariates

We explored the variables associated with statin prescription to determine candidate variables for the propensity score of statin treatment. From SIDIAP^Q we obtained data on age, sex, systolic and diastolic blood pressure, body mass index, vascular risk factors (diabetes, hypertension, hypercholesterolemia, smoking, high alcohol consumption), other comorbidities at baseline (atrial fibrillation, arthritis, asthma, chronic obstructive pulmonary disease, hypothyroidism), other drugs (non-statin lipid lowering drugs, diuretics, β blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, antidiabetics, anti-inflammatory drugs, aspirin), and laboratory tests (total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglycerides, glucose, glycated haemoglobin, glomerular filtration rate). For each participant, we also recorded the number of visits and a deprivation index.³⁰

Statistical analysis

We present categorical variables as percentages and continuous variables as means (standard deviations) or their 95% confidence intervals, or medians (interquartile ranges), as appropriate.

The number of imputations performed was defined according to efficiency and reproducibility based on the fraction of missing information, which measures the impact of the overall missing percentage on the estimated hazard of interest (use of statin).³¹ To replace missing baseline values of total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglycerides, glucose, systolic and diastolic blood pressure, and body mass index, we used 10 multiple imputations by chained equations.³¹ The supplementary file describes the process of multiple imputation and the variables considered in the models. Supplementary material (eTable1) describes the missing data patterns. In addition to incorporating the missing-at-random assumption, we compared case complete results with multiple imputation as a sensitivity analysis (see supplementary file).

Because of non-random treatment allocation, we used a logistic model based on potential confounding

covariates to calculate the propensity score of statin treatment (see supplementary file for details on the development and assessment of the propensity score model). We calculated the propensity score separately for participants with and without diabetes and also within each age group, and standardised differences before and after adjustment for propensity score. Variables with standardised differences <0.10 were considered to be well balanced.

Using Cox proportional hazard regression models adjusted by propensity score, we calculated the hazard ratios of statin use for the outcome events. Participants were censored at the date of transfer from SIDIAP^Q or at the end of the study period. For each group (based on age and type 2 diabetes status) in each imputed dataset we calculated 10 propensity scores and 10 hazard ratios. A pooled hazard ratio was then calculated according to Rubin's rules, with propensity score as covariate. To prevent residual confounding we performed additional regression adjustments after adjustment of propensity score. Variables that remained imbalanced after propensity score adjustment were also included in the models. The proportionality of hazards assumption was tested. We also calculated the absolute risk reductions and one year number needed to treat for one additional patient to survive without reaching an endpoint.

We analysed the data using a simulated intention to treat scenario, where subsequent changes in treatment of the participants who used or did not use statins did not modify the category of use or study ending time. In an additional sensitivity analysis, we used a Fine-Gray semiparametric proportional subdistribution hazards model for the main cardiovascular outcomes, considering all cause mortality as a competitive event. This model was also adjusted by the same propensity score used in the Cox model.

We stratified all the analyses by diabetic status. For the relation of age with effect of statins, we performed two parallel statistical analyses. The first was a categorical approach stratifying the analysis by age group: old (75-84 years) and very old (≥ 85 years). The second was a continuous analysis using an additive Cox proportional hazard model. To model the effect of age in users and non-users separately we used thin plate regression splines.

All statistical analyses were carried out using R software.^{32 33}

Patient involvement

No patients were involved in setting the research question or the outcome measures, nor were they involved in the design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There are plans to disseminate the results of the research to the relevant patient community.

Results

Between July 2006 and December 2007, 46 864 people fulfilled the inclusion criteria, of whom 7502 (16.0%)




Fig 1 | Flowchart of participant selection. SIDIAP^Q=Information System for the Development of Research in Primary Care

started statin treatment (fig 1). Median follow-up was 7.7 years (interquartile range 7.2-8.0 years). The highest fraction of missing information associated with the hazard of interest (use of statins) was less than 0.1. Therefore, 10 imputations would be enough to ensure efficiency and reproducibility. Table 1 shows the proportion of missing data for incomplete variables and a comparison of the complete case dataset and imputed dataset. Mean values of these variables remained similar after multiple imputations.

Of those participants included, 7880 (16.8%) had type 2 diabetes. Among those without diabetes, women constituted 64.4% and the mean age was 80.8 (SD 4.7) years. Overall, 58.8% of participants had hypertension, 11.5% were smokers, and 25.5% had hypercholesterolemia. Close to 85% of new users were treated with a statin of low or moderate capacity to reduce low density lipoprotein levels. Among participants with diabetes, 60.4% were women with a mean age of 80.5 (SD 4.3) years. Hypertension was

present in 76.2% of participants, 13.7% were smokers, and hypercholesterolemia was present in 29.2%. More than 85% of statin new users with type 2 diabetes were treated with a statin of low and moderate capacity to reduce low density lipoprotein levels.

Tables 2 and 3 show the baseline characteristics for statin new users and non-users by age group and presence of type 2 diabetes. After adjustment for propensity score, no statistically significant or clinically relevant standardised differences were observed.

Statin effectiveness

Number of events, event rates per 1000 person years, and hazard ratios (95% confidence intervals) of coronary heart disease, stroke, atherosclerotic CVD, and mortality in the 75-84 years and 85 years or older age groups are presented for participants without diabetes (table 4) and for those with diabetes (table 5). The proportionality of hazards assumption was met in all the groups and for all the outcomes except for coronary heart disease in the population aged 85 or older with diabetes, in which case we considered a time exposure interaction in evaluating the Cox model.

In participants without diabetes, the hazard ratios for statin use were 0.94 (95% confidence interval 0.86 to 1.04) for atherosclerotic CVD and 0.98 (0.91 to 1.05) for all cause mortality in 75-84 year olds. Similarly, no benefit was observed for participants without diabetes aged 85 years and older: 0.93 (0.82 to 1.06) for atherosclerotic CVD and 0.97 (0.90 to 1.05) for all cause mortality. In participants with diabetes, the hazard ratios for statin use were 0.76 (0.65 to 0.89) for atherosclerotic CVD and 0.84 (0.75 to 0.94) for all cause mortality in 75-84 year olds. The one year number needed to treat was 164 for atherosclerotic CVD and 306 for all cause mortality. In participants with diabetes aged 85 years and older, the hazard ratios were 0.82 (0.53 to 1.26) for atherosclerotic CVD and 1.05 (0.86 to 1.28) for all cause mortality.

Table 1 | Mean (95% confidence interval) of variables with missing data in complete case dataset (observed values) and imputed dataset, by presence of diabetes

Variables	Missing values (%)	Observed values	Imputed values
Participants without diabetes:			
Total cholesterol (mmol/L)	12 432 (31.9)	5.5 (5.5 to 5.5)	5.4 (5.4 to 5.4)
HDL cholesterol (mmol/L)	17 028 (43.7)	1.6 (1.5 to 1.6)	1.5 (1.5 to 1.6)
LDL cholesterol (mmol/L)	17 138 (44.0)	3.4 (3.4 to 3.4)	3.3 (3.3 to 3.3)
Triglycerides (mmol/L)	15 849 (40.7)	1.3 (1.2 to 1.3)	1.2 (1.2 to 1.2)
Glucose (mmol/L)	12 125 (31.1)	5.3 (5.3 to 5.3)	5.3 (5.3 to 5.3)
Systolic blood pressure (mm Hg)	5 118 (13.1)	137.8 (137.6 to 138.0)	137.4 (137.2 to 137.6)
Diastolic blood pressure (mm Hg)	5 436 (13.9)	74.8 (74.7 to 75.0)	75.1 (75.0 to 75.2)
Body mass index	10 752 (27.6)	28.6 (28.6 to 28.7)	28.1 (28.1 to 28.1)
Participants with diabetes:			
Total cholesterol (mmol/L)	1 279 (16.2)	5.2 (5.2 to 5.2)	5.2 (5.1 to 5.2)
HDL cholesterol (mmol/L)	1 599 (20.3)	1.4 (1.4 to 1.4)	1.4 (1.4 to 1.4)
LDL cholesterol (mmol/L)	1 606 (20.4)	3.2 (3.1 to 3.2)	3.1 (3.1 to 3.1)
Triglycerides (mmol/L)	1 478 (18.8)	1.5 (1.5 to 1.5)	1.5 (1.4 to 1.5)
Glucose (mmol/L)	1 183 (15.0)	7.8 (7.7 to 7.8)	7.7 (7.7 to 7.8)
Systolic blood pressure (mm Hg)	341 (4.3)	140.6 (140.2 to 141.1)	140.6 (140.2 to 140.9)
Diastolic blood pressure (mm Hg)	408 (5.2)	74.7 (74.4 to 74.9)	74.6 (74.4 to 74.9)
Body mass index	801 (10.2)	29.4 (29.2 to 29.5)	29.2 (29.1 to 29.3)

HDL=high density lipoprotein; LDL=low density lipoprotein.




Fig 2 | Thin plate regression splines of hazard ratios of atherosclerotic cardiovascular disease and all cause mortality for statin use, by age, in participants with and without type 2 diabetes mellitus

Similarly, in the estimation of hazard ratios for each year of age (fig 2), those for the use of statins remained close to 1 in participants without diabetes and statistically non-significant, regardless of the age, for atherosclerotic CVD and all cause mortality. In contrast, in participants with diabetes the hazard ratios showed a statistically significant and clinically relevant (ranging from 0.7 to 0.8) reduction in atherosclerotic CVD. This reduction lost statistical significance at age 85 years. Statins also showed a protective effect against all cause mortality in participants with diabetes; however, this effect began to lose statistical significance at age 82 years and definitively disappeared in participants aged 88 years or more (fig 2).

The case complete analysis showed no statistically or clinically relevant differences from the hazard ratio obtained in the analysis of the dataset with multiple imputations (see supplementary eTable 2). The same occurred with the competing risk analysis, which did not differ from the Cox analysis (eTable 3). We observed no significant increase of adverse events attributable to statins (tables 4 and 5).

Discussion

Our results show a lack of association between statin treatment and reduction in atherosclerotic CVD events or all cause mortality in the absence of type 2 diabetes mellitus in old and very old groups, although the incidence (ie, risk) of atherosclerotic CVD in both age groups (table 4) was significantly higher than the risk thresholds proposed for statin use in the guidelines for cardiovascular prevention.¹⁷⁻¹⁹ In participants with diabetes, however, statins significantly reduced

the incidence of atherosclerotic CVD, by 24%, and all cause mortality, by 16%, in participants aged 75-84 years. No benefits were observed in participants with type 2 diabetes in aged 85 years or older. These results do not support the widespread use of statins in old and very old populations, but they do support statin treatment in selected people such as those aged 75-84 years with type 2 diabetes. Similarly, the analysis of the effect of age in a continuous scale using splines corroborated the lack of beneficial effect of statins for atherosclerotic CVD and for all cause mortality in participants without diabetes and older than 74 years. Statins showed a protective effect against atherosclerotic CVD in participants with diabetes, which began to lose statistical significance at age 85 years and definitively disappeared in those aged 92 years or older. Statins also showed a protective effect against all cause mortality in participants with diabetes, which began to lose statistical significance at 83 years of age and definitively disappeared in those aged 90 years or older. These results are clinically plausible because age itself may be the main contributor to death at these advanced ages. However, we acknowledge the limited sample size of the group of participants with diabetes aged 85 years or older, with few statin new users and few events and therefore with limited statistical power. We cannot rule out the possibility that this small sample was responsible for the lack of effect observed. Larger observational and clinical studies are needed to elucidate the effect of statins in this subgroup. In addition, the relatively low baseline low density lipoprotein cholesterol level in people with diabetes

Table 2 | Baseline characteristics of statin new users and non-users without type 2 diabetes mellitus by age group, using standardised differences of the mean before and after adjustment for propensity score. Values are numbers (percentages) unless stated otherwise

Characteristics	75-84 years				≥85 years			
	Statin non-users (n=27 114)	Statin new users (n=4802)	Standardised difference	Adjusted standardised difference	Statin non-users (n=6325)	Statin new users (n=743)	Standardised difference	Adjusted standardised difference
Mean (SD) age (years)	79.1 (2.8)	78.8 (2.7)	0.13	0.03	88.6 (3.2)	88.5 (3.2)	0.06	0.05
Men	10 086 (37.2)	16 76 (34.9)	0.05	0.01	1910 (30.2)	224 (30.2)	-0.00	0.03
Smoker	3362 (12.4)	648 (13.5)	-0.03	0.01	424 (6.7)	58 (7.8)	-0.04	0.04
Hypertension	15 536 (57.3)	3155 (65.7)	-0.17	0.08	3713 (58.7)	496 (66.8)	-0.17	0.06
Hypercholesterolemia	5938 (21.9)	2607 (54.3)	-0.71	0.09	1069 (16.9)	314 (42.2)	-0.58	0.23
Obesity	9734 (35.9)	1801 (37.5)	-0.03	0.05	1493 (23.6)	203 (27.3)	-0.09	0.13
Mean (SD) body mass index	28.4 (4.6)	28.6 (4.6)	-0.06	0.05	27.6 (4.5)	27.1 (4.3)	-0.08	0.13
Mean (SD) pulse pressure	61.8 (14.6)	61.7 (14.8)	0.00	0.01	64.9 (16.4)	65.3 (16.9)	-0.02	0.03
Mean (SD) systolic blood pressure (mm Hg)	137.1 (16.2)	137.4 (16.3)	-0.02	0.02	138.5 (17.8)	138.9 (17.5)	-0.02	0.07
Mean (SD) diastolic blood pressure (mm Hg)	75.4 (9.1)	75.7 (9.2)	-0.03	0.05	73.6 (9.6)	73.5 (9.4)	0.01	0.07
Mean (SD) total cholesterol (mmol/L)	5.4 (0.9)	6.1 (1.1)	-0.78	0.16	5.2 (0.9)	5.9 (1.2)	-0.63	0.03
Mean (SD) LDL cholesterol (mmol/L)	3.3 (0.7)	3.9 (1.0)	-0.77	0.17	3.1 (0.8)	3.7 (1.0)	-0.64	0.03
Mean (SD) HDL cholesterol (mmol/L)	1.5 (0.4)	1.5 (0.4)	0.00	0.02	1.6 (0.4)	1.5 (0.4)	0.07	0.02
Mean (SD) serum triglycerides (mmol/L)	1.2 (0.5)	1.4 (0.7)	-0.36	0.02	1.2 (0.5)	1.4 (0.6)	-0.37	0.02
Drugs:								
Aspirin	2115 (7.8)	812 (16.9)	-0.28	0.13	841 (13.3)	198 (26.6)	-0.34	0.13
Diuretic	6209 (22.9)	1546 (32.2)	-0.21	0.10	1727 (27.3)	308 (41.4)	-0.30	0.13
β blocker	1898 (7.0)	586 (12.2)	-0.18	0.08	304 (4.8)	87 (11.7)	-0.25	0.07
ACE inhibitor/ARB	9354 (34.5)	2430 (50.6)	-0.33	0.16	2113 (33.4)	416 (56.0)	-0.47	0.15
Calcium channel blocker	2928 (10.8)	831 (17.3)	-0.19	0.13	797 (12.6)	166 (22.4)	-0.26	0.05
Non-statin lipid lowering drugs	434 (1.6)	192 (4.0)	-0.14	0.07	76 (1.2)	21 (2.8)	-0.12	0.06
Anti-inflammatory drugs	7321 (27.0)	1714 (35.7)	-0.19	0.09	1202 (19.0)	221 (29.8)	-0.25	0.13
Antidiabetes treatment	271 (1.0)	250 (5.2)	-0.25	0.13	51 (0.8)	49 (6.6)	-0.31	0.06
Statin by LDL reduction capacity:								
Low (≤30%)	—	331 (6.9)	—	—	—	65 (8.8)	—	—
Moderate (31-40%)	—	3755 (78.2)	—	—	—	549 (73.9)	—	—
High (41-50%)	—	691 (14.4)	—	—	—	127 (17.1)	—	—
Very high (>50%)	—	24 (0.5)	—	—	—	2 (0.3)	—	—
Comorbidities:								
Atrial fibrillation	1573 (5.8)	264 (5.5)	0.01	0.01	474 (7.5)	72 (9.7)	-0.08	0.04
COPD	2766 (10.2)	490 (10.2)	0.00	0.01	626 (9.9)	75 (10.1)	-0.01	0.05
Arthritis	352 (1.3)	62 (1.3)	-0.00	0.01	70 (1.1)	5 (0.7)	0.04	0.02
Asthma	1166 (4.3)	221 (4.6)	-0.01	0.02	196 (3.1)	24 (3.2)	-0.01	0.00
Hypothyroidism	1247 (4.6)	226 (4.7)	-0.01	0.00	221 (3.5)	27 (3.7)	-0.01	0.07
Mean (SD) No of visits	20.1 (23.2)	23.4 (23.7)	-0.14	0.10	18.4 (22.5)	19.6 (23.2)	-0.05	0.10
Deprivation index*:								
1 (most deprived)	2983 (11.0)	543 (11.3)	-0.01	0.02	841 (13.3)	114 (15.3)	-0.06	0.03
2	4013 (14.8)	768 (16.0)	-0.03	0.03	1012 (16.7)	126 (17.0)	-0.01	0.01
3	4636 (17.1)	912 (19.0)	-0.05	0.02	1082 (17.1)	121 (16.3)	0.02	0.03
4	4908 (18.1)	898 (18.7)	-0.02	0.04	993 (15.7)	117 (15.7)	0.00	0.06
5 (least deprived)	4826 (17.8)	826 (17.2)	0.02	0.01	85 (13.5)	106 (14.3)	-0.02	0.01

HDL=high density lipoprotein; LDL=low density lipoprotein; ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker; COPD=chronic obstructive pulmonary disease.

*Based on census data in large Spanish cities (the MEDEA project).³⁰

aged 85 years or older could have contributed to the observed lack of effect in this group.

A possible survival effect should also be considered. Study participants had reached age 75 years with no vascular disease, which could partially explain the limited effect size of statin treatment observed in this population. Finally, we cannot dismiss the possibility that a proportion of non-statin users might have taken statins previous to the washout period, potentially allowing a lagged effect of some statins that could partially explain the observed lack of differences between users and non-users without type 2 diabetes.³⁴

It is rather complex to establish a precise cut-off point for the age at which statins no longer have a

beneficial effect in people with diabetes. However, in our data the effect was substantially reduced after age 85 years and disappeared in nonagenarians.

Comparison with other studies

The effectiveness of statins for primary prevention in people aged 75 years or older has elicited wide controversy.³⁵ The only clinical trial specifically designed for elderly people, the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), included patients aged 70-82 years (mean 75 years), with a high proportion of participants in secondary prevention of CVD. Although no beneficial effect was found in the subanalysis including only participants in primary prevention.³⁶

Table 3 | Comparison of baseline characteristics of statin new users and non-users with type 2 diabetes mellitus by age group, using standardised differences of the mean before and after adjustment for propensity score. Values are numbers (percentages) unless stated otherwise

Characteristics	75-84 years				≥85 years			
	Statin non-users (n=4885)	Statin new users (n=1756)	Standardised difference	Adjusted standardised difference	Statin non-users (n=1038)	Statin new users (n=201)	Standardised difference	Adjusted standardised difference
Mean (SD) age (years)	79.2 (2.8)	78.8 (2.6)	0.16	0.04	88.2 (2.7)	88.2 (2.8)	-0.03	0.15
Men	2052 (42.0)	680 (38.7)	0.07	0.04	332 (32.0)	66 (32.8)	-0.02	0.20
Smoker	718 (14.7)	270 (15.4)	-0.02	0.04	85 (8.2)	13 (6.5)	0.07	0.01
Hypertension	3669 (75.1)	1377 (78.4)	-0.08	0.02	787 (75.8)	166 (82.6)	-0.17	0.10
Hypercholesterolemia	1065 (21.8)	938 (53.4)	-0.70	0.05	233 (22.4)	7 (39.3)	-0.37	0.02
Obesity	2262 (46.3)	867 (49.4)	-0.06	0.01	345 (33.2)	77 (38.2)	-0.10	0.03
Mean (SD) body mass index	29.4 (4.8)	29.7 (4.7)	-0.08	0.00	27.5 (4.4)	28.2 (4.3)	-0.17	0.04
Mean (SD) pulse pressure	65.4 (15.5)	65.9 (16.3)	-0.03	0.02	68.0 (17.4)	66.3 (15.2)	0.11	0.02
Mean (SD) systolic blood pressure (mm Hg)	140.3 (17.2)	141.0 (18.0)	-0.04	0.01	141.0 (18.5)	138.7 (16.7)	0.13	0.02
Mean (SD) diastolic blood pressure (mm Hg)	74.9 (9.6)	75.1 (9.6)	-0.03	0.02	73.0 (9.9)	72.4 (10.6)	0.05	0.01
Mean (SD) total cholesterol (mmol/L)	5.0 (0.8)	5.8 (1.1)	-0.84	0.20	5.0 (0.9)	5.5 (1.1)	-0.42	0.22
Mean (SD) LDL cholesterol (mmol/L)	3.0 (0.7)	3.7 (0.9)	-0.85	0.17	3.0 (0.7)	3.3 (1.0)	-0.40	0.19
Mean (SD) HDL cholesterol (mmol/L)	1.4 (0.4)	1.4 (0.4)	0.05	0.06	1.4 (0.4)	1.4 (0.3)	0.15	0.04
Mean (SD) serum triglycerides (mmol/L)	1.4 (0.7)	1.7 (0.8)	-0.38	0.06	1.4 (0.7)	1.6 (0.9)	-0.33	0.04
Drugs:								
Aspirin	1045 (21.4)	543 (30.9)	-0.22	0.16	227 (21.9)	73 (36.3)	-0.32	0.09
Diuretic	1382 (28.3)	567 (32.3)	-0.09	0.05	324 (31.2)	81 (40.3)	-0.19	0.11
β blocker	474 (9.7)	216 (12.3)	-0.08	0.02	63 (6.1)	21 (10.5)	-0.16	0.05
ACE inhibitor/ARB	2716 (55.6)	1198 (68.2)	-0.26	0.12	548 (52.8)	143 (71.1)	-0.38	0.13
Calcium channel blocker	933 (19.1)	397 (22.6)	-0.09	0.09	216 (20.8)	69 (34.3)	-0.31	0.09
Non-statin lipid lowering drugs	220 (4.5)	104 (5.9)	-0.07	0.07	23 (2.2)	9 (4.5)	-0.13	0.09
Anti-inflammatory drugs	1329 (27.2)	536 (30.5)	-0.07	0.06	212 (20.4)	52 (25.9)	-0.13	0.12
Antidiabetes treatment	3136 (64.2)	1282 (73.0)	-0.19	0.11	608 (58.6)	130 (64.7)	-0.13	0.02
Statin by LDL reduction capacity:								
Low (≤30%)	—	107 (6.1)	—	—	—	11 (5.5)	—	—
Moderate (31-40%)	—	1398 (79.6)	—	—	—	150 (74.6)	—	—
High (41-50%)	—	248 (14.1)	—	—	—	39 (19.4)	—	—
Very high (>50%)	—	4 (0.2)	—	—	—	1 (0.5)	—	—
Comorbidities:								
Atrial fibrillation	366 (7.5)	11 (6.6)	0.04	0.04	99 (9.5)	20 (10.0)	-0.01	0.06
COPD	542 (11.1)	170 (9.7)	0.05	0.00	98 (9.4)	20 (10.0)	-0.02	0.05
Arthritis	49 (1.0)	18 (1.0)	0.00	0.03	7 (0.7)	2 (1.0)	-0.03	0.08
Asthma	215 (4.4)	81 (4.6)	-0.01	0.00	44 (4.2)	6 (3.0)	0.07	0.05
Hypothyroidism	225 (4.6)	105 (6.0)	-0.06	0.02	44 (4.2)	7 (3.5)	0.04	0.09
Mean (SD) No of visits	28.1 (29.0)	30.4 (28.3)	-0.08	0.09	24.9 (26.4)	27.1 (26.6)	-0.09	0.10
Deprivation index*:								
1 (most deprived)	449 (9.2)	162 (9.2)	0.00	0.03	127 (12.2)	28 (13.9)	-0.05	0.09
2	664 (13.6)	242 (13.8)	-0.00	0.02	154 (14.8)	33 (16.4)	-0.04	0.11
3	860 (17.6)	307 (17.5)	0.00	0.01	184 (17.7)	40 (19.9)	-0.06	0.04
4	962 (19.7)	335 (19.1)	0.02	0.02	180 (17.3)	24 (11.9)	0.15	0.03
5 (least deprived)	1006 (20.6)	393 (22.4)	-0.04	0.01	184 (17.7)	27 (13.4)	0.06	0.03

HDL=high density lipoprotein; LDL=low density lipoprotein; ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker; COPD=chronic obstructive pulmonary disease.

*Based on census data in large Spanish cities (the MEDEA project).³⁰

There are studies supporting the benefit of statins on cardiovascular disease but not on mortality. Within the JUPITER trial (Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin), a subanalysis of patients older than 70 years (median 74 years), showed a 39% reduction of CVD in participants treated with statins, but no beneficial effect on mortality.³⁷ Two meta-analyses have also addressed the statin effect in cardiovascular primary prevention.⁸⁹ Savarese et al included participants older than 65 years (mean 73 years) and found that statins were associated with a statistically significant reduction in the incidence of myocardial infarction and stroke but not in overall mortality.⁸ Teng et al also included patients older than 65 years (mean 72.7 years), but found statins to be significantly effective only in reducing the

incidence of myocardial infarction but not of stroke or overall mortality.⁹

Finally, the HOPE-3 (Heart Outcomes Prevention Evaluation) trial assessed the benefit of statins in those aged 65 years or older (mean 70.8 years) and found a protective effect on the incidence of the composite outcome including death from cardiovascular causes and non-fatal myocardial infarction or stroke.³⁸

Extrapolations of these findings to the population aged 75 years or older should be done with caution because all these studies included a large proportion of participants younger than 75 years, leading the results towards the beneficial effect of statins observed in younger people. In a recently published post hoc analysis of the ALLHAT-LLT study,¹² which included patients with both hyperlipidaemia and hypertension, the authors performed a subanalysis including

Table 4 | Hazard ratios of incident cardiovascular events and mortality and one year number needed to treat to prevent one event by use of statins in participants without type 2 diabetes mellitus by age group: intention to treat analysis

Variables	Statin non-users		Statin new users		Hazard ratio (95% CI)	NNT
	No of events	Incidence rate/ 1000 person years (95% CI)	No of events	Incidence rate/ 1000 person years (95% CI)		
75-84 years n=27 114						
Outcomes of interest:						
Coronary heart disease	1328	7.1 (6.7 to 7.5)	270	8.2 (7.2 to 9.1)	0.94 (0.81 to 1.09)	—
Stroke	2066	11.2 (10.7 to 11.6)	364	11.1 (9.9 to 12.2)	0.94 (0.83 to 1.07)	—
Atherosclerotic CVD	3229	17.8 (17.2 to 18.4)	600	18.8 (17.3 to 20.3)	0.94 (0.86 to 1.04)	—
All cause mortality	7075	37.0 (36.1 to 37.8)	1109	32.6 (30.7 to 34.5)	0.98 (0.91 to 1.05)	—
Adverse effects:						
Cancer	4125	27.3 (26.5 to 28.2)	730	27.1 (25.2 to 29.1)	1.02 (0.93 to 1.11)	—
Haemorrhagic stroke	639	3.9 (3.6 to 4.2)	98	3.4 (2.7 to 4.0)	0.89 (0.70 to 1.13)	—
Diabetes	2133	13.8 (13.2 to 14.4)	430	15.8 (14.3 to 17.3)	1.02 (0.90 to 1.15)	—
Hepatotoxicity	13	0.5 (0.2 to 0.7)	2	0.4 (–0.2 to 1.0)	1.01 (0.20 to 4.99)	—
Myopathy	12	0.5 (0.2 to 0.7)	0	0.0 (0.0 to 0.0)	—	—
≥85 years n=6325						
Outcomes of interest:						
Coronary heart disease	254	7.6 (6.7 to 8.5)	38	9.6 (6.5 to 12.6)	0.84 (0.58 to 1.24)	—
Stroke	581	17.8 (16.3 to 19.2)	83	21.7 (17.0 to 26.3)	1.10 (0.85 to 1.41)	—
Atherosclerotic CVD	801	24.9 (23.2 to 26.6)	115	30.6 (25.0 to 36.2)	1.00 (0.80 to 1.24)	—
All cause mortality	4077	120.0 (116.3 to 123.7)	471	116.2 (105.7 to 126.8)	1.00 (0.90 to 1.11)	—
Adverse effects:						
Cancer	734	28.5 (26.4 to 30.6)	87	28.6 (22.6 to 34.6)	0.92 (0.72 to 1.17)	—
Haemorrhagic stroke	145	5.3 (4.4 to 6.1)	19	5.8 (3.2 to 8.4)	1.13 (0.67 to 1.92)	—
Diabetes	336	12.6 (11.3 to 14.0)	41	13.1 (9.1 to 17.1)	0.87 (0.60 to 1.26)	—
Hepatotoxicity	0	—	0	—	—	—
Myopathy	7	1.1 (0.3 to 2.0)	0	—	—	—

CVD=cardiovascular disease.

726 people aged 75 years or older (375 receiving pravastatin and 351 receiving usual care) and found no reduction in all cause mortality or in CVD. Our results in participants without type 2 diabetes are in line with those of the ALLHAT-LLT study.

However, no previous studies had specifically analysed the effect of statins in people with diabetes aged 75 years or older, and we found a different scenario from that observed in participants without type 2 diabetes: the observed benefits were not only statistically significant but also clinically relevant, because statin treatment was associated with an absolute reduction in cardiovascular events of about 7 per 1000 people treated for one year and more than 3 per 1000 individuals treated for one year in overall mortality in the group aged 75-84 years. These results are in accordance with the idea that diabetes increases the risk of vascular events and mortality regardless of age, and this increase is even more pronounced in people who have had diabetes long term,³⁹ or when multiple cardiovascular risk factors coexist,⁴⁰ as is common among older people. In our study, participants with type 2 diabetes had a higher prevalence of other cardiovascular risk factors (hypertension, hypercholesterolemia, tobacco use, obesity) than the general population of the same age (tables 2 and 3), and the incidence of cardiovascular disease in those with diabetes was more than 50% higher than in those without diabetes.

Implications of findings

Our results support the need to individualise the decision making process about statin treatment in

old and very old populations. Tools exist to predict CVD risk in patients aged up to 79 years,¹⁹ or even 84 years,⁴¹ but older populations are heterogeneous, with diverse life expectancy, different degrees of frailty or special comorbid conditions, and use of drug combinations. Thus, specific risk prediction tools are more appropriate for these older people.⁴² Shorter term (ie, five year) prediction tools may be reasonable in older people, because life expectancy at older ages is limited.⁴³ Inclusion of information about functional capacity in the risk prediction also could make sense because Cruz et al reported that everyday functional capacity has a greater impact on 10 year mortality risk in very old people compared with traditional cardiovascular risk factors.⁴⁴

Following current guidelines, most of the population in our study would be suitable candidates for statin treatment because the incidence of CVD in the control group was well above the risk threshold of 10%. However, statins were only protective in those with type 2 diabetes and younger than 85 years. Thus, our results do not support these recommendations in old and very old people without diabetes, and they raise an important question: whether the current risk threshold for statin indication (10% risk of atherosclerotic CVD at 10 years) is appropriate in this population.

Adverse effects

Statin use was not associated with an increased risk of myopathy, liver toxicity, or incidence of type 2 diabetes. An increased incidence of diabetes,^{45 46} myopathy,⁴⁷ and hepatopathy⁴⁸ has been reported, mostly in intensive regimens; in our study, 85% of

Table 5 | Hazard ratios of incident cardiovascular events and mortality and one year number needed to treat to prevent one event by use of statins in participants with type 2 diabetes mellitus by age group: intention to treat analysis

Variables	Statin non-users		Statin new users		Hazard ratio (95% CI)	NNT
	No of events	Incidence rate/ 1000 person years (95% CI)	No of events	Incidence rate/ 1000 person years (95% CI)		
75-84 years n=4885						
Outcomes of interest:						
Coronary heart disease	385	12.4 (11.2 to 13.7)	125	10.6 (8.7 to 12.5)	0.75 (0.60 to 0.94)	341
Stroke	525	17.1 (15.6 to 18.5)	165	14.2 (12.0 to 16.4)	0.81 (0.66 to 0.99)	384
Atherosclerotic CVD	865	29.2 (27.2 to 31.1)	271	24.0 (21.1 to 26.8)	0.76 (0.65 to 0.89)	164
All cause mortality	1752	54.5 (52.0 to 57.1)	503	41.5 (37.9 to 45.2)	0.84 (0.75 to 0.94)	306
Adverse effects:						
Cancer	733	29.3 (27.2 to 31.4)	258	26.7 (23.4 to 30.0)	0.93 (0.79 to 1.10)	—
Haemorrhagic stroke	157	5.8 (4.9 to 6.7)	49	4.8 (3.4 to 6.1)	0.96 (0.67 to 1.38)	—
Hepatotoxicity	1	0.2 (−0.2 to 0.6)	3	0.6 (−0.1 to 1.3)	—	—
Myopathy	1	0.2 (−0.2 to 0.6)	0	—	—	—
≥85 years n=1038						
Outcomes of interest:						
Coronary heart disease	57	11.5 (8.5 to 14.6)	14	13.9 (6.6 to 21.1)	1.15 (0.58 to 2.28)	—
Stroke	107	22.1 (17.9 to 26.3)	16	15.8 (8.1 to 23.6)	0.66 (0.37 to 1.17)	—
Atherosclerotic CVD	159	33.5 (28.2 to 38.7)	30	30.6 (19.6 to 41.5)	0.82 (0.53 to 1.26)	—
All cause mortality	696	137.0 (126.8 to 147.2)	140	134.6 (112.3 to 156.9)	1.05 (0.86 to 1.28)	—
Adverse effects:						
Cancer	117	31.0 (25.4 to 36.7)	17	21.3 (11.2 to 31.4)	0.64 (0.37 to 1.10)	—
Haemorrhagic stroke	18	4.4 (2.4 to 6.5)	6	7.3 (1.4 to 12.8)	1.96 (0.67 to 5.75)	—
Hepatotoxicity	0	—	—	—	—	—
Myopathy	1	1.0 (−0.98 to 3.0)	0	—	—	—

CVD=cardiovascular disease.

statin regimens were of low to medium potency. Additionally, mild myopathy or hepatopathy could be underestimated in electronic medical records. In line with previous studies, our results showed no increased risk of cancer or haemorrhagic stroke associated with statin use.^{49 50} Even so, the possibility that longer duration of statin use might have shown an increased incidence of diabetes, cancer, or haemorrhagic stroke cannot be dismissed.

Study characteristics and limitations that merit consideration

A major strength of this study was the high quality, internally validated, database of electronic medical records that provided a large sample size, ensured high external validity,²⁴ and reflected real life clinical conditions by including participants often excluded from clinical trials. For instance, the high proportion of women in our study coincides with the general population in this age group.⁵¹ Furthermore, data on statin use were obtained from official pharmacy invoicing records of the national health service.

Several general limitations are inherent to observational studies using medical records. Firstly, residual confounding is a possibility, especially by indication; we used a new users design and then adjusted by propensity score in each age group and stratum of type 2 diabetes status. Additionally, we used sample restriction (excluding patients with cancer, dementia, or paralysis and those receiving dialysis, in residential care, or with an organ transplant) to reduce the healthy user bias.⁵² Despite these efforts, we acknowledge that some residual confounding might exist. This would affect the results because propensity score adjustment can account for some confounding

but not all. The lack of data indicating ethnicity is another limitation of the study. Our database does not include this variable. Although ethnicity could potentially affect the study results, it is reasonable to assume that the study population is mostly white. In Catalonia, the immigrant population is known to represent a small percentage (<3.5%) of the reference population older than 74 years—that is, most of the population is white. Secondly, missing data can influence results. We imputed the missing values of the continuous variables in the study to avoid the selection bias that might occur when excluding such records.

The percentage of missing data ranged from 4.3% (systolic blood pressure) to 20.4% (low density lipoprotein cholesterol) in participants with type 2 diabetes, and from 13.1% (systolic blood pressure) to 43.9% (low density lipoprotein cholesterol) in participants without diabetes, and the characteristics of the complete case analysis did not differ from those of the imputed data (eTable 2). Thirdly, we could not analyse the effect of statins on cardiovascular death, as cause of death is not available in the SIDIAP^Q database. We also cannot exclude some underreporting of outcomes, which could lead to non-differential misclassification and reduce statistical power, biasing the results towards the null hypothesis. This issue is especially relevant for the incidence of hepatotoxicity, myopathy, myalgia, fatigue, or weakness, which have an important impact on older people's quality of life. Future studies should strive to involve patients in evaluating statin use to capture their point of view and experience with the drug. Fourthly, we applied prescription time-distribution matching; random index dates were assigned to the non-users matching the distribution of the users' date of first prescription.⁵³

This prevents an imbalance in prescription time-distribution between the two groups, which can generate a survival bias.⁵³ Finally, limited statistical power was a weakness in our study, which restricts the possibility of performing a comparative analysis of some subgroups, such as patients receiving treatment with high or very high versus moderate to low intensity statins.

These results, based on observational data, may not provide enough grounds for direct clinical recommendations, but they do show the need for randomised clinical trials to further elucidate this problem. Statins for Reducing Events in the Elderly (STAREE study) is a promising ongoing trial on CVD primary prevention that compares atorvastatin (40 mg) with placebo in healthy people older than 70 years,⁵⁴ but until publication of the STAREE results, expected in 2022, our findings may help to make decisions in clinical practice. Ethnicity differences, sociocultural aspects, lifespan, and characteristics of health systems should be considered when extrapolating these results to other countries. The population lifespan in Catalonia at birth (83.2 years) is higher than the average lifespan in Europe (80.6 years),⁵¹ and the public health system provides universal healthcare, including prescriptions, to the whole population, including the present study population (≥ 74 years old).

Conclusions

The effect of statin treatment in primary prevention in the older population varies depending on the presence of type 2 diabetes. Statins were not associated with a reduction in atherosclerotic CVD or in all cause mortality in participants without diabetes aged 75 years or older and free of clinical CVD. In participants with type 2 diabetes, however, statins were significantly related to a reduction in the incidence of atherosclerotic CVD and in all cause mortality. This effect was substantially reduced after the age of 85 years and disappeared in nonagenarians.

These results do not support the widespread use of statins in old and very old populations, but they do support treatment in those with type 2 diabetes younger than 85 years.

AUTHOR AFFILIATIONS

¹Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Catalonia, Spain

²ISV Research Group. Research Unit in Primary Care, Primary Care Services, Girona. Catalan Institute of Health, Catalonia, Spain

³Institut d'Investigació Biomèdica de Girona (IdIBGi), Catalonia, Spain

⁴Department of Medical Sciences, School of Medicine, University of Girona, Spain

⁵Registre Gironí del COR Group (REGICOR); Cardiovascular, Epidemiology and Genetics Research Group (EGEC), Municipal Institute for Medical Research (IMIM), Barcelona, Spain

⁶CIBER of Cardiovascular Diseases, Barcelona, Catalonia, Spain

⁷Institute of Biomedical Research of Salamanca, Primary Care Research Unit, the Alamedilla Health Center, Castilla and León Health Service-SACYL, and Department of Biomedical and Diagnostic Sciences, University of Salamanca, Salamanca, Spain
We thank the Registry of the Minimum Basic Data Set, Services and Quality Area, Catalan Health Service, for providing hospital discharge

data. This paper has not been prepared in collaboration with these registries and thus it does not necessarily reflect their opinions or points of view. Only the authors take responsibility for the integrity of the data and the accuracy of the data analysis. We also thank Elaine Lilly for revising the English.

Contributors: RR, MG-G, and MC-C conceived and designed the study. MC-C and JB acquired the data. All authors analysed and interpreted the data. RR and MG-G drafted the manuscript. All authors critically revised the manuscript for important intellectual content. MC-C, JB, and MG-G carried out the statistical analysis. RR and MG-G obtained funding. RM-L, AP, LA-C, JB, and ME-B provided administrative, technical, or material support. RR, MG-G, MC-C, and EB supervised the study. RR and MG-G are guarantors. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding: This project was supported by clinical research grants from the Ministerio de Salud (EC11-267); Spain's Ministry of Science and Innovation through the Carlos III Health Institute, co-financed with European Union ERDF funds (Network for Prevention and Health Promotion in primary Care (RedIAPP RD16/0007/0004); the Red de Investigación Cardiovascular (RD12/0042/0061, RD12/0042/0013) and Miguel Servet Contract CP12/03287); and by the Departament de Salut, Generalitat de Catalunya, Agency for Management of University and Research Grants (2014 SGR 240; 2017 SGR 1146). The sponsors had no role in the design and conduct of the study; the collection, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Ethics approval for observational research using SIDIAP^Q data was obtained from the local ethics committee. Informed consent of individual patients was not required as anonymised information was obtained from medical records. In the SIDIAP^Q database, confidentiality is rigorously assured by a standardised system of codification that involves all possible identifier variables, which are not available to investigators.

Data sharing: No additional data available.

Transparency: The lead author (RR) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

- 1 Statistics WH. Geneva. World Health Organization, 2015. [cited 2018 Jan 7], http://www.who.int/gho/publications/world_health_statistics/2015/.
- 2 Marrugat J, Sala J, Manresa JM, et al. REGICOR Investigators. Acute myocardial infarction population incidence and in-hospital management factors associated to 28-day case-fatality in the 65 year and older. *Eur J Epidemiol* 2004;19:231-7. doi:10.1023/B:EJEP.0000020446.57845.b0
- 3 Ageing WP. 1950-2050. New York. United Nations, 2001. [cited 2018 Jan 10], <http://www.un.org/esa/population/publications/worldageing19502050/>.
- 4 Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). *Circulation* 1997;96:4211-8. doi:10.1161/01.CIR.96.12.4211
- 5 Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. *Ann Intern Med* 1998;129:681-9. doi:10.7326/0003-4819-129-9-199811010-00002
- 6 Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. *Ann Intern Med* 2001;134:931-40. doi:10.7326/0003-4819-134-10-200105150-00007

- 7 Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. *J Am Coll Cardiol* 2008;51:37-45. doi:10.1016/j.jacc.2007.06.063
- 8 Savarese G, Gotto AM Jr, Paolillo S, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. *J Am Coll Cardiol* 2013;62:2090-9. doi:10.1016/j.jacc.2013.07.069
- 9 Teng M, Lin L, Zhao YJ, et al. Statins for Primary Prevention of Cardiovascular Disease in Elderly Patients: Systematic Review and Meta-Analysis. *Drugs Aging* 2015;32:649-61. doi:10.1007/s40266-015-0290-9
- 10 Konrat C, Boutron I, Trinquart L, Auleley GR, Ricordeau P, Ravaud P. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. *PLoS One* 2012;7:e33559. doi:10.1371/journal.pone.0033559
- 11 Collerton J, Davies K, Jagger C, et al. Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study. *BMJ* 2009;339:b4904. doi:10.1136/bmj.b4904
- 12 Han BH, Sutin D, Williamson JD, et al, ALLHAT Collaborative Research Group. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. *JAMA Intern Med* 2017;177:955-65. doi:10.1001/jamainternmed.2017.1442
- 13 Rana JS, Liu JY, Moffet HH, Jaffe M, Karter AJ. Diabetes and Prior Coronary Heart Disease are Not Necessarily Risk Equivalent for Future Coronary Heart Disease Events. *J Gen Intern Med* 2016;31:387-93. doi:10.1007/s11606-015-3556-3
- 14 Olafsdottir E, Aspelund T, Sigurdsson G, et al. Effects of statin medication on mortality risk associated with type 2 diabetes in older persons: the population-based AGES-Reykjavik Study. *BMJ Open* 2011;1:e000132. doi:10.1136/bmjopen-2011-000132
- 15 Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. *JAMA* 2015;314:1818-31. doi:10.1001/jama.2015.13766
- 16 O'Keefe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data. *Clin Epidemiol* 2016;8:123-32. doi:10.2147/CLEP.S104258
- 17 Piepoli MF, Hoes AW, Agewall S, et al, ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J* 2016;37:2315-81. doi:10.1093/eurheartj/ehw106
- 18 National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. CG181. London: NICE (UK); 2014. [cited 2018 Jan 15]. <https://www.nice.org.uk/guidance/cg181>.
- 19 Goff DC Jr, Lloyd-Jones DM, Bennett G, et al, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014;63(25 Pt B):2935-59. doi:10.1016/j.jacc.2013.11.005
- 20 Ueda P, Lung TW, Clarke P, Danaei G. Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis. *Br J Gen Pract* 2017;67:e598-608. doi:10.3399/bjgp17X692141
- 21 Thai M, Reeve E, Hilmer SN, Qi K, Pearson SA, Gnjjidic D. Prevalence of statin-drug interactions in older people: a systematic review. *Eur J Clin Pharmacol* 2016;72:513-21. doi:10.1007/s00228-016-2011-7
- 22 Bolibar B, Fina Avilés F, Morros R, et al, Grupo SIDIAP. [SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research]. *Med Clin (Barc)* 2012;138:617-21.
- 23 García-Gil M del M, Hermosilla E, Prieto-Alhambra D, et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). *Inform Prim Care* 2011;19:135-45.
- 24 Ramos R, Balló E, Marrugat J, et al. Validity for use in research on vascular diseases of the SIDIAP (Information System for the Development of Research in Primary Care): the EMMA study. *Rev Esp Cardiol (Engl Ed)* 2012;65:29-37. doi:10.1016/j.rec.2011.07.016
- 25 Ramos R, García-Gil M, Comas-Cufí M, et al. Statins for Prevention of Cardiovascular Events in a Low-Risk Population With Low Ankle Brachial Index. *J Am Coll Cardiol* 2016;67:630-40. doi:10.1016/j.jacc.2015.11.052
- 26 García-Gil M, Blanch J, Comas-Cufí M, et al. Patterns of statin use and cholesterol goal attainment in a high-risk cardiovascular population: A retrospective study of primary care electronic medical records. *J Clin Lipidol* 2016;10:134-42. doi:10.1016/j.jacl.2015.10.007
- 27 Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *Am J Epidemiol* 2003;158:915-20. doi:10.1093/aje/kwg231
- 28 Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. *J Clin Pharm Ther* 2010;35:139-51. doi:10.1111/j.1365-2710.2009.01085.x
- 29 Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. *Br J Clin Pharmacol* 2009;67:99-109. doi:10.1111/j.1365-2125.2008.03308.x
- 30 Domínguez-Berjón MF, Borrell C, Cano-Serral G, et al. [Constructing a deprivation index based on census data in large Spanish cities (the MEDEA project)]. *Gac Sanit* 2008;22:179-87.
- 31 White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Stat Med* 2011;30:377-99. doi:10.1002/sim.4067
- 32 R Development Core Team. (2011). R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing (Austria); 2011 [cited 2017 Aug 25] <http://www.R-project.org/>.
- 33 Stef van Buuren. Karin Groothuis-Oudshoorn. MICE: Multivariate Imputation by Chained Equations in R. *J Stat Softw* 2011;45:1-67.
- 34 Ford I, Murray H, McCowan C, Packard CJ. Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. *Circulation* 2016;133:1073-80. doi:10.1161/CIRCULATIONAHA.115.019014
- 35 Strandberg TE, Kolehmainen L, Vuorio A. Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. *JAMA* 2014;312:1136-44. doi:10.1001/jama.2014.10924
- 36 Shepherd J, Blauw GJ, Murphy MB, et al, PROSPER study group. PROSpective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002;360:1623-30. doi:10.1016/S0140-6736(02)11600-X
- 37 Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. *Ann Intern Med* 2010;152:488-96, W174. doi:10.7326/0003-4819-152-8-201004200-00005
- 38 Yusuf S, Bosch J, Dagenais G, et al, HOPE-3 Investigators. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. *N Engl J Med* 2016;374:2021-31. doi:10.1056/NEJMoa1600176
- 39 Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. *Arch Intern Med* 2011;171:404-10. doi:10.1001/archinternmed.2011.2
- 40 Howard BV, Best LG, Galloway JM, et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. *Diabetes Care* 2006;29:391-7. doi:10.2337/diacare.29.02.06.dc05-1299
- 41 Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. *BMJ* 2008;336:1475-82. doi:10.1136/bmj.39609.449676.25
- 42 Cooney MT, Selmer R, Lindman A, et al, SCORE and CONOR investigators. Cardiovascular risk estimation in older persons: SCORE O.P. *Eur J Prev Cardiol* 2016;23:1093-103. doi:10.1177/2047487315588390
- 43 Life expectancy at birth, at 65, and 75 years of age by sex, race and Hispanic origin. Health, United States, 2016. Atlanta: National Center for Health Statistics (US); 2016 [cited 2018 Jan 21]. <http://www.cdc.gov/nchs/fastats/life-expectancy.htm>.
- 44 Cruz M, Covinsky K, Widera EW, Stijacic-Cenzer I, Lee SJ. Predicting 10-year mortality for older adults. *JAMA* 2013;309:874-6. doi:10.1001/jama.2013.1184
- 45 Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet* 2010;375:735-42. doi:10.1016/S0140-6736(09)61965-6
- 46 Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. *JAMA* 2011;305:2556-64. doi:10.1001/jama.2011.860
- 47 Armitage J, Bowman L, Wallendszus K, et al, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. *Lancet* 2010;376:1658-69. doi:10.1016/S0140-6736(10)60310-8

- 48 Gotto AM Jr. Risks and benefits of continued aggressive statin therapy. *Clin Cardiol* 2003;26(Suppl 3):III3-12. doi:10.1002/clc.4960261503
- 49 Emberson JR, Kearney PM, Blackwell L, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. *PLoS One* 2012;7:e29849. doi:10.1371/journal.pone.0029849
- 50 McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. *Stroke* 2012;43:2149-56. doi:10.1161/STROKEAHA.112.655894
- 51 Idescat.cat. Barcelona: Institut d'Estadística de Catalunya (Spain); 2018 [cited 2018 May 11]. <http://www.idescat.cat/>.
- 52 McGrath LJ, Ellis AR, Brookhart MA. Controlling Time-Dependent Confounding by Health Status and Frailty: Restriction Versus Statistical Adjustment. *Am J Epidemiol* 2015;182:17-25. doi:10.1093/aje/kwu485
- 53 Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. *Am J Epidemiol* 2005;162:1016-23. doi:10.1093/aje/kwi307
- 54 NIH. ClinicalTrials.gov. A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE); 2014 [cited 2018 Jan 26]. <https://clinicaltrials.gov/ct2/show/NCT02099123>.

Supplementary information: additional material